Carbiotix se declara en quiebra

La empresa de biotecnología Carbiotix, con sede en Lund, ha sido declarada en quiebra. La firma fue excluida de cotización en Spotlight Stock Market a finales del año pasado.

Patrik Kalman, administrador concursal del bufete de abogados Trägårdh, mantuvo conversaciones con la dirección de la empresa. No ve condiciones para continuar con las operaciones. La quiebra implica una liquidación pura. Los activos se venderán en subasta en breve. Carbiotix fue fundada en 2014 por Kristofer Cook. La empresa desarrolló tecnología para ingredientes prebióticos a partir de flujos de residuos de origen vegetal, principalmente para la industria alimentaria.

Artículos relacionados

Grifols executives in boardroom approving minority stake IPO for US Biopharma business, with surging stock charts on screens.
Imagen generada por IA

Grifols prepares stock listing for its US Biopharma business

Reportado por IA Imagen generada por IA

Grifols' board has approved preparing a public offering (OPV) of a minority stake in its US Biopharma business to reduce debt and fund growth. The company will retain majority control and continue listing in Spain. Its ADRs surged up to 13% in after-hours trading.

Claessons Snickeri Aktiebolag in Krylbo has been declared bankrupt following its own request. Falu District Court made the decision on June 8.

Reportado por IA

Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.

Finance profile Günther Mårder, detained on Friday suspected of serious insider trading offences, has requested to leave his role on the Swedish Public Employment Service board and resigned from RaySearch Laboratories.

Reportado por IA

Patent AI company Lightbringer has raised over 90 million kronor in a Series A round led by 6 Degrees Capital and Newion.

Bootstrap Bio and Manhattan Genomics, biotech firms launched last year to pursue human embryo editing for preventing serious diseases, have closed their doors. The companies cited financial difficulties and internal conflicts as reasons for the shutdowns. The developments highlight challenges in the controversial field of gene-edited babies.

Reportado por IA

No bids have been placed yet on the bankrupt ski resort in Näsfjället, Sälen. Bankruptcy administrator Henric Schef says there have been interested parties, but none have submitted offers. The resort has been for sale since autumn.

 

 

 

Este sitio web utiliza cookies

Utilizamos cookies para análisis con el fin de mejorar nuestro sitio. Lee nuestra política de privacidad para más información.
Rechazar